Key facts
- This page summarizes Craig Eagle's Form 4 filing for Guardant Health, Inc. (GH).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 13 Mar 2025, 16:32.
Craig Eagle - 12 Mar 2025 Form 4 Insider Report for Guardant Health, Inc. (GH)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- GH
- Reported as of
- 12 Mar 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 13 Mar 2025, 16:32:18 UTC
- Prior SEC filing
- 04 Mar 2025
- Next SEC filing
- 18 Mar 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ John G. Saia, as attorney-in-fact for Craig Eagle
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Craig Eagle filed Form 4 for Guardant Health, Inc. (GH) on 13 Mar 2025.
Change
- Previous filing in this sequence was filed on 04 Mar 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
GH
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +24,363
- Change %
- Price
- $0.000000
- Shares after
- 24,363
- Date
- 12 Mar 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 24,363
- Exercise price
- $43.10
- Footnotes
- F1
GH
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +16,242
- Change %
- Price
- $0.000000
- Shares after
- 16,242
- Date
- 12 Mar 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 16,242
- Exercise price
- $0.000000
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
This represents a stock option award granted on March 12, 2025 that vests over a three-year period. 33% of the shares subject to such award vests on April 1, 2026, and the remaining 67% of the shares vests in equal monthly installments over the remaining two-year period thereafter.
Footnote F2
This represents a restricted stock unit award granted on March 12, 2025 that vests over a three-year period. 33% of the shares subject to such award vests on April 1, 2026, and the remaining 67% of the shares vest in equal quarterly installments over the remaining two-year period thereafter.
Footnote F3
Not applicable for Restricted Stock Units.